{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:17:39Z","timestamp":1790396259880,"version":"4.1.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG 2018 - ID. 21325"],"award-info":[{"award-number":["IG 2018 - ID. 21325"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF\u20102021\u201012372851; CUPF83C22002620001"],"award-info":[{"award-number":["RF\u20102021\u201012372851; CUPF83C22002620001"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["The Grant of Excellence Departments 2023-2027, MIUR (ARTICOLO 1, COMMI 314 \u2013 337 LEGGE 232\/2016) to the Department of Science"],"award-info":[{"award-number":["The Grant of Excellence Departments 2023-2027, MIUR (ARTICOLO 1, COMMI 314 \u2013 337 LEGGE 232\/2016) to the Department of Science"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-025-02639-5","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:57:35Z","timestamp":1767592655000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The natural L370F ER\u03b1 variant confers endocrine resistance and sensitivity to ATRA in metastatic breast cancer cells"],"prefix":"10.1186","volume":"24","author":[{"given":"Manuela","family":"Cipolletti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Bellucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Fiocchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matic","family":"Pavlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Magistrato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Acconcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"2639_CR1","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41568-023-00604-3","volume":"23","author":"M Will","year":"2023","unstructured":"Will M, Liang J, Metcalfe C, Chandarlapaty S. Therapeutic resistance to anti-oestrogen therapy in breast cancer. Nat Rev Cancer. 2023;23:673\u201385. https:\/\/doi.org\/10.1038\/s41568-023-00604-3.","journal-title":"Nat Rev Cancer"},{"key":"2639_CR2","doi-asserted-by":"publisher","unstructured":"Shah M, Lingam H, Gao X, Gittleman H, Fiero MH, Krol D, Biel N, Ricks TK, Fu W, Hamed S, Li F, Sun JJ, Fan J, Schuck R, Grimstein M, Tang L, Kalavar S, Abukhdeir A, Pathak A, Ghosh S, Bulatao I, Tilley A, Pierce WF, Mixter BD, Tang S, Pazdur R, Kluetz P, Amiri-Kordestani. L 2024 US food and drug administration approval summary: elacestrant for Estrogen receptor-Positive, human epidermal growth factor receptor 2-Negative, ESR1-Mutated advanced or metastatic breast cancer. J Clin Oncol:JCO2302112. https:\/\/doi.org\/10.1200\/JCO.23.02112.","DOI":"10.1200\/JCO.23.02112"},{"key":"2639_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41523-023-00523-4","volume":"9","author":"R Patel","year":"2023","unstructured":"Patel R, Klein P, Tiersten A, Sparano JA. An emerging generation of endocrine therapies in breast cancer: a clinical perspective. NPJ Breast Cancer. 2023;9:20. https:\/\/doi.org\/10.1038\/s41523-023-00523-4.","journal-title":"NPJ Breast Cancer"},{"key":"2639_CR4","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s11864-023-01079-y","volume":"24","author":"M Shastry","year":"2023","unstructured":"Shastry M, Hamilton E. Novel Estrogen Receptor-Targeted agents for breast cancer. Curr Treat Options Oncol. 2023;24:821\u201344. https:\/\/doi.org\/10.1007\/s11864-023-01079-y.","journal-title":"Curr Treat Options Oncol"},{"key":"2639_CR5","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/S1470-2045(24)00387-5","volume":"25","author":"M Oliveira","year":"2024","unstructured":"Oliveira M, Pominchuk D, Nowecki Z, Hamilton E, Kulyaba Y, Andabekov T, et al. Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial. Lancet Oncol. 2024;25:1424\u201339. https:\/\/doi.org\/10.1016\/S1470-2045(24)00387-5.","journal-title":"Lancet Oncol"},{"key":"2639_CR6","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/JCO.22.00338","volume":"40","author":"FC Bidard","year":"2022","unstructured":"Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol. 2022;40:3246\u201356. https:\/\/doi.org\/10.1200\/JCO.22.00338.","journal-title":"J Clin Oncol"},{"key":"2639_CR7","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.annonc.2024.04.012","volume":"35","author":"E Hamilton","year":"2024","unstructured":"Hamilton E, Oliveira M, Turner N, Garcia-Corbacho J, Hernando C, Ciruelos EM, et al. A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results. Ann Oncol. 2024;35:707\u201317. https:\/\/doi.org\/10.1016\/j.annonc.2024.04.012.","journal-title":"Ann Oncol"},{"key":"2639_CR8","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1146\/annurev-med-052423-122001","volume":"76","author":"N Pathak","year":"2025","unstructured":"Pathak N, Oliveira M. New oral selective Estrogen receptor degraders redefine management of Estrogen receptor-Positive breast cancer. Annu Rev Med. 2025;76:243\u201355. https:\/\/doi.org\/10.1146\/annurev-med-052423-122001.","journal-title":"Annu Rev Med"},{"key":"2639_CR9","doi-asserted-by":"publisher","unstructured":"Jhaveri KL, Neven P, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P, Saura C, O\u2019Shaughnessy J, Harbeck N, Carey LA, Curigliano G, Llombart-Cussac A, Lim E, Garcia Tinoco ML, Sohn J, Mattar A, Zhang Q, Huang CS, Hung CC, Martinez Rodriguez JL, Ruiz Borrego M, Nakamura R, Pradhan KR, von Cramer C, Barrett E, Cao S, Wang XA, Smyth LM. Bidard FC and group E-S 2025 imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med. 392:1189\u2013202. https:\/\/doi.org\/10.1056\/NEJMoa2410858.","DOI":"10.1056\/NEJMoa2410858"},{"key":"2639_CR10","doi-asserted-by":"publisher","unstructured":"Keam SJ. Imlunestrant: First Approval. Drugs. 2025. https:\/\/doi.org\/10.1007\/s40265-025-02266-x. Epub ahead of print.","DOI":"10.1007\/s40265-025-02266-x"},{"key":"2639_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22062915","author":"M Cipolletti","year":"2021","unstructured":"Cipolletti M, Bartoloni S, Busonero C, Parente M, Leone S, Acconcia F. A new anti-estrogen discovery platform identifies FDA-approved imidazole anti-fungal drugs as bioactive compounds against ER\u03b1 expressing breast cancer cells. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22062915.","journal-title":"Int J Mol Sci"},{"key":"2639_CR12","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.1002\/1878-0261.13303","volume":"16","author":"S Bartoloni","year":"2022","unstructured":"Bartoloni S, Leone S, Pescatori S, Cipolletti M, Acconcia F. The antiviral drug Telaprevir induces cell death by reducing FOXA1 expression in Estrogen receptor alpha (ERalpha)-positive breast cancer cells. Mol Oncol. 2022;16:3568\u201384. https:\/\/doi.org\/10.1002\/1878-0261.13303.","journal-title":"Mol Oncol"},{"key":"2639_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123840","author":"C Busonero","year":"2020","unstructured":"Busonero C, Leone S, Bianchi F, Maspero E, Fiocchetti M, Palumbo O, et al. Ouabain and digoxin activate the proteasome and the degradation of the ER\u03b1 in cells modeling primary and metastatic breast cancer. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12123840.","journal-title":"Cancers (Basel)"},{"key":"2639_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-022-02360-y","volume":"41","author":"S Pescatori","year":"2022","unstructured":"Pescatori S, Leone S, Cipolletti M, Bartoloni S, di Masi A, Acconcia F. Clinically relevant CHK1 inhibitors abrogate wild\u2011type and Y537S mutant ER\u03b1 expression and proliferation in luminal primary and metastatic breast cancer cells. J Exp Clin Cancer Res. 2022;41:27. https:\/\/doi.org\/10.1186\/s13046-022-02360-y.","journal-title":"J Exp Clin Cancer Res"},{"key":"2639_CR15","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1002\/cncr.32345","volume":"125","author":"D Dustin","year":"2019","unstructured":"Dustin D, Gu G, Fuqua SAW. ESR1 mutations in breast cancer. Cancer. 2019;125:3714\u201328. https:\/\/doi.org\/10.1002\/cncr.32345.","journal-title":"Cancer"},{"key":"2639_CR16","doi-asserted-by":"publisher","DOI":"10.1172\/JCI163242","author":"S Irani","year":"2024","unstructured":"Irani S, Tan W, Li Q, Toy W, Jones C, Gadiya M, et al. Somatic estrogen receptor \u03b1 mutations that induce dimerization promote receptor activity and breast cancer proliferation. J Clin Invest. 2024. https:\/\/doi.org\/10.1172\/JCI163242.","journal-title":"J Clin Invest"},{"key":"2639_CR17","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1158\/2159-8290.CD-22-1387","volume":"14","author":"B Kingston","year":"2024","unstructured":"Kingston B, Pearson A, Herrera-Abreu MT, Sim LX, Cutts RJ, Shah H, et al. ESR1 F404 mutations and acquired resistance to fulvestrant in ESR1-mutant breast cancer. Cancer Discov. 2024;14:274\u201389. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-1387.","journal-title":"Cancer Discov"},{"key":"2639_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17364-4","volume":"8","author":"M Pavlin","year":"2018","unstructured":"Pavlin M, Spinello A, Pennati M, Zaffaroni N, Gobbi S, Bisi A, et al. A computational assay of Estrogen Receptor \u03b1 antagonists reveals the key common structural traits of drugs effectively fighting refractory breast cancers. Sci Rep. 2018;8:649. https:\/\/doi.org\/10.1038\/s41598-017-17364-4.","journal-title":"Sci Rep"},{"key":"2639_CR19","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/39645","volume":"389","author":"AM Brzozowski","year":"1997","unstructured":"Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 1997;389:753\u20138. https:\/\/doi.org\/10.1038\/39645.","journal-title":"Nature"},{"key":"2639_CR20","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1038\/onc.2016.382","volume":"36","author":"A Harrod","year":"2017","unstructured":"Harrod A, Fulton J, Nguyen VTM, Periyasamy M, Ramos-Garcia L, Lai CF, et al. Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer. Oncogene. 2017;36:2286\u201396. https:\/\/doi.org\/10.1038\/onc.2016.382.","journal-title":"Oncogene"},{"key":"2639_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-59001-x","volume":"14","author":"S Bartoloni","year":"2024","unstructured":"Bartoloni S, Pescatori S, Bianchi F, Cipolletti M, Acconcia F. Selective impact of ALK and MELK inhibition on ER\u03b1 stability and cell proliferation in cell lines representing distinct molecular phenotypes of breast cancer. Sci Rep. 2024;14:8200. https:\/\/doi.org\/10.1038\/s41598-024-59001-x.","journal-title":"Sci Rep"},{"key":"2639_CR22","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1128\/MCB.25.3.1054-1069.2005","volume":"25","author":"H Srinivas","year":"2005","unstructured":"Srinivas H, Juroske DM, Kalyankrishna S, Cody DD, Price RE, Xu XC, et al. C-Jun N-terminal kinase contributes to aberrant retinoid signaling in lung cancer cells by phosphorylating and inducing proteasomal degradation of retinoic acid receptor alpha. Mol Cell Biol. 2005;25:1054\u201369. https:\/\/doi.org\/10.1128\/MCB.25.3.1054-1069.2005.","journal-title":"Mol Cell Biol"},{"key":"2639_CR23","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1210\/me.2014-1385","volume":"29","author":"P Totta","year":"2015","unstructured":"Totta P, Pesiri V, Enari M, Marino M, Acconcia F. Clathrin heavy chain interacts with Estrogen receptor alpha and modulates 17beta-estradiol signaling. Mol Endocrinol. 2015;29:739\u201355. https:\/\/doi.org\/10.1210\/me.2014-1385.","journal-title":"Mol Endocrinol"},{"key":"2639_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.29565","author":"M Cipolletti","year":"2020","unstructured":"Cipolletti M, Leone S, Bartoloni S, Busonero C, Acconcia F. Real-time measurement of E2: ERalpha transcriptional activity in living cells. J Cell Physiol. 2020. https:\/\/doi.org\/10.1002\/jcp.29565.","journal-title":"J Cell Physiol"},{"key":"2639_CR25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3390\/endocrines2010006","volume":"2","author":"M Cipolletti","year":"2021","unstructured":"Cipolletti M, Pescatori S, Acconcia F. Real-time challenging of ER\u03b1 Y537S mutant transcriptional activity in living cells. Endocrines. 2021;2:54\u201364. https:\/\/doi.org\/10.3390\/endocrines2010006.","journal-title":"Endocrines"},{"key":"2639_CR26","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/ng.2822","volume":"45","author":"W Toy","year":"2013","unstructured":"Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA, Hudis C, Chen D, Taran T, Hortobagyi G, Greene G, Berger M, Baselga J, Chandarlapaty S. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013;45:1439\u201345. https:\/\/doi.org\/10.1038\/ng.2822.","journal-title":"Nat Genet"},{"key":"2639_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1083\/jcb.200604150","volume":"174","author":"LM Hoffman","year":"2006","unstructured":"Hoffman LM, Garcha K, Karamboulas K, Cowan MF, Drysdale LM, Horton WA, et al. BMP action in skeletogenesis involves attenuation of retinoid signaling. J Cell Biol. 2006;174:101\u201313. https:\/\/doi.org\/10.1083\/jcb.200604150.","journal-title":"J Cell Biol"},{"key":"2639_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-023-04768-4","volume":"6","author":"P Rafii","year":"2023","unstructured":"Rafii P, Seibel C, Weitz HT, Ettich J, Minafra AR, Petzsch P, et al. Cytokimera GIL-11 rescued IL-6R deficient mice from partial hepatectomy-induced death by signaling via non-natural gp130:LIFR:IL-11R complexes. Commun Biol. 2023;6:418. https:\/\/doi.org\/10.1038\/s42003-023-04768-4.","journal-title":"Commun Biol"},{"key":"2639_CR29","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ab.2004.05.055","volume":"332","author":"Z Nikolovska-Coleska","year":"2004","unstructured":"Nikolovska-Coleska Z, Wang R, Fang X, Pan H, Tomita Y, Li P, Roller PP, Krajewski K, Saito NG, Stuckey JA, Wang S. Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization. Anal Biochem. 2004;332:261\u201373. https:\/\/doi.org\/10.1016\/j.ab.2004.05.055.","journal-title":"Anal Biochem"},{"key":"2639_CR30","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","volume":"22","author":"Y Cheng","year":"1973","unstructured":"Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973;22:3099\u2013108. https:\/\/doi.org\/10.1016\/0006-2952(73)90196-2.","journal-title":"Biochem Pharmacol"},{"key":"2639_CR31","unstructured":"Case DAea. 2020 AMBER 2020. University of California, San Francisco. https:\/\/ambermd.org\/."},{"key":"2639_CR32","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1021\/acs.jctc.9b00591","volume":"16","author":"C Tian","year":"2020","unstructured":"Tian C, Kasavajhala K, Belfon KAA, Raguette L, Huang H, Migues AN, et al. Ff19SB: amino-acid-specific protein backbone parameters trained against quantum mechanics energy surfaces in solution. J Chem Theory Comput. 2020;16:528\u201352. https:\/\/doi.org\/10.1021\/acs.jctc.9b00591.","journal-title":"J Chem Theory Comput"},{"key":"2639_CR33","doi-asserted-by":"publisher","DOI":"10.1063\/1.464397","author":"TY Darden","year":"1993","unstructured":"Darden TY, Pedersen L. Particle mesh Ewald: an N\u22c5log(N) method for Ewald sums in large systems. J Chem Phys. 1993. https:\/\/doi.org\/10.1063\/1.464397.","journal-title":"J Chem Phys"},{"key":"2639_CR34","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1103\/physreva.33.3628","volume":"33","author":"GS Grest","year":"1986","unstructured":"Grest GS, Kremer K. Molecular dynamics simulation for polymers in the presence of a heat bath. Phys Rev Gen Phys. 1986;33:3628\u201331. https:\/\/doi.org\/10.1103\/physreva.33.3628.","journal-title":"Phys Rev Gen Phys"},{"key":"2639_CR35","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1063\/1.448118","volume":"81","author":"HJCP Berendsen","year":"1984","unstructured":"Berendsen HJCP, van Gunsteren WF, Di Nola A, Haak JR. Molecular dynamics with coupling to an external bath. J Chem Phys. 1984;81:3684\u201390. https:\/\/doi.org\/10.1063\/1.448118.","journal-title":"J Chem Phys"},{"key":"2639_CR36","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/0021-9991(77)90098-5","volume":"23","author":"J-PC Rickaert","year":"1977","unstructured":"Rickaert J-PC, Berendsen G, H.J.C. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys. 1977;23:327\u201341. https:\/\/doi.org\/10.1016\/0021-9991(77)90098-5.","journal-title":"J Comput Phys"},{"key":"2639_CR37","unstructured":"Case DAea. 2022 AmberTools22. University of California, San Francisco. https:\/\/ambermd.org\/."},{"key":"2639_CR38","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.cellsig.2011.02.006","volume":"23","author":"P La Rosa","year":"2011","unstructured":"La Rosa P, Pesiri V, Marino M, Acconcia F. 17 beta-Estradiol-induced cell proliferation requires Estrogen receptor (ER) alpha monoubiquitination. Cell Signal. 2011;23:1128\u201335. https:\/\/doi.org\/10.1016\/j.cellsig.2011.02.006.","journal-title":"Cell Signal"},{"key":"2639_CR39","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1002\/jcp.26251","volume":"233","author":"S Leone","year":"2018","unstructured":"Leone S, Busonero C, Acconcia F. A high throughput method to study the physiology of E2:ERalpha signaling in breast cancer cells. J Cell Physiol. 2018;233:3713\u201322. https:\/\/doi.org\/10.1002\/jcp.26251.","journal-title":"J Cell Physiol"},{"key":"2639_CR40","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41568-018-0001-z","volume":"18","author":"JA Katzenellenbogen","year":"2018","unstructured":"Katzenellenbogen JA, Mayne CG, Katzenellenbogen BS, Greene GL, Chandarlapaty S. Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance. Nat Rev Cancer. 2018;18:377\u201388. https:\/\/doi.org\/10.1038\/s41568-018-0001-z.","journal-title":"Nat Rev Cancer"},{"key":"2639_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2024.112160","volume":"584","author":"M Cipolletti","year":"2024","unstructured":"Cipolletti M, Acconcia F. <article-title update=\"added\">PMM2 controls ER\u03b1 levels and cell proliferation in ESR1 Y537S variant expressing breast cancer cells. Mol Cell Endocrinol. 2024;584:112160. https:\/\/doi.org\/10.1016\/j.mce.2024.112160.","journal-title":"Mol Cell Endocrinol"},{"key":"2639_CR42","doi-asserted-by":"publisher","first-page":"4905","DOI":"10.1038\/s41388-022-02483-8","volume":"41","author":"A Harrod","year":"2022","unstructured":"Harrod A, Lai CF, Goldsbrough I, Simmons GM, Oppermans N, Santos DB, et al. Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer. Oncogene. 2022;41:4905\u201315. https:\/\/doi.org\/10.1038\/s41388-022-02483-8.","journal-title":"Oncogene"},{"key":"2639_CR43","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1210\/me.2011-1208","volume":"26","author":"P La Rosa","year":"2012","unstructured":"La Rosa P, Pesiri V, Leclercq G, Marino M, Acconcia F. Palmitoylation regulates 17beta-estradiol-induced estrogen receptor-alpha degradation and transcriptional activity. Mol Endocrinol. 2012;26:762\u201374. https:\/\/doi.org\/10.1210\/me.2011-1208.","journal-title":"Mol Endocrinol"},{"key":"2639_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2021.111452","volume":"538","author":"F Acconcia","year":"2021","unstructured":"Acconcia F, Fiocchetti M, Busonero C, Fernandez VS, Montalesi E, Cipolletti M, et al. The extra-nuclear interactome of the estrogen receptors: implications for physiological functions. Mol Cell Endocrinol. 2021;538:111452. https:\/\/doi.org\/10.1016\/j.mce.2021.111452.","journal-title":"Mol Cell Endocrinol"},{"key":"2639_CR45","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/nmeth.1226","volume":"5","author":"A Mortazavi","year":"2008","unstructured":"Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods. 2008;5:621\u20138. https:\/\/doi.org\/10.1038\/nmeth.1226.","journal-title":"Nat Methods"},{"key":"2639_CR46","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nbt.1621","volume":"28","author":"C Trapnell","year":"2010","unstructured":"Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010;28:511\u20135. https:\/\/doi.org\/10.1038\/nbt.1621.","journal-title":"Nat Biotechnol"},{"key":"2639_CR47","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417\u201325. https:\/\/doi.org\/10.1016\/j.cels.2015.12.004.","journal-title":"Cell Syst"},{"key":"2639_CR48","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1158\/0008-5472.CAN-23-0539","volume":"83","author":"Z Li","year":"2023","unstructured":"Li Z, Li T, Yates ME, Wu Y, Ferber A, Chen L, et al. The EstroGene database reveals diverse temporal, context-dependent, and bidirectional estrogen receptor regulomes in breast cancer. Cancer Res. 2023;83:2656\u201374. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-0539.","journal-title":"Cancer Res"},{"key":"2639_CR49","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/s0092-8674(00)81717-1","volume":"95","author":"AK Shiau","year":"1998","unstructured":"Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, et al. The structural basis of estrogen receptor\/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 1998;95:927\u201337. https:\/\/doi.org\/10.1016\/s0092-8674(00)81717-1.","journal-title":"Cell"},{"key":"2639_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2019.00602","volume":"7","author":"M Pavlin","year":"2019","unstructured":"Pavlin M, Gelsomino L, Barone I, Spinello A, Catalano S, Ando S, et al. <article-title update=\"added\">Structural, thermodynamic, and kinetic traits of antiestrogen-compounds selectively targeting the Y537S mutant estrogen receptor \u03b1 transcriptional activity in breast cancer cell lines. Front Chem. 2019;7:602. https:\/\/doi.org\/10.3389\/fchem.2019.00602.","journal-title":"Front Chem"},{"key":"2639_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1254612","volume":"11","author":"K Lavudi","year":"2023","unstructured":"Lavudi K, Nuguri SM, Olverson Z, Dhanabalan AK, Patnaik S, Kokkanti RR. Targeting the retinoic acid signaling pathway as a modern precision therapy against cancers. Front Cell Dev Biol. 2023;11:1254612. https:\/\/doi.org\/10.3389\/fcell.2023.1254612.","journal-title":"Front Cell Dev Biol"},{"key":"2639_CR52","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3892\/ijo.2015.3013","volume":"47","author":"A Shilkaitis","year":"2015","unstructured":"Shilkaitis A, Green A, Christov K. Retinoids induce cellular senescence in breast cancer cells by RAR-beta dependent and independent pathways: potential clinical implications (review). Int J Oncol. 2015;47:35\u201342. https:\/\/doi.org\/10.3892\/ijo.2015.3013.","journal-title":"Int J Oncol"},{"key":"2639_CR53","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","volume":"66","author":"AN Blackford","year":"2017","unstructured":"Blackford AN, Jackson SP. ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response. Mol Cell. 2017;66:801\u201317. https:\/\/doi.org\/10.1016\/j.molcel.2017.05.015.","journal-title":"Mol Cell"},{"key":"2639_CR54","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.tcb.2018.02.001","volume":"28","author":"A Hernandez-Segura","year":"2018","unstructured":"Hernandez-Segura A, Nehme J, Demaria M. Hallmarks of cellular senescence. Trends Cell Biol. 2018;28:436\u201353. https:\/\/doi.org\/10.1016\/j.tcb.2018.02.001.","journal-title":"Trends Cell Biol"},{"key":"2639_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071815","author":"M Milczarek","year":"2020","unstructured":"Milczarek M. The premature senescence in breast cancer treatment strategy. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12071815.","journal-title":"Cancers (Basel)"},{"key":"2639_CR56","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2009.04.043","volume":"137","author":"S Hua","year":"2009","unstructured":"Hua S, Kittler R, White KP. Genomic antagonism between retinoic acid and estrogen signaling in breast cancer. Cell. 2009;137:1259\u201371. https:\/\/doi.org\/10.1016\/j.cell.2009.04.043.","journal-title":"Cell"},{"key":"2639_CR57","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1101\/gad.552910","volume":"24","author":"CS Ross-Innes","year":"2010","unstructured":"Ross-Innes CS, Stark R, Holmes KA, Schmidt D, Spyrou C, Russell R, et al. Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer. Genes Dev. 2010;24:171\u201382. https:\/\/doi.org\/10.1101\/gad.552910.","journal-title":"Genes Dev"},{"key":"2639_CR58","doi-asserted-by":"crossref","unstructured":"Metivier R, Penot G, Hubner MR, Reid G, Brand H, Kos M, Gannon. F 2003 Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 115:751\u201363. https:\/\/doi.org\/S0092867403009346.","DOI":"10.1016\/S0092-8674(03)00934-6"},{"key":"2639_CR59","doi-asserted-by":"crossref","unstructured":"Reid G, Hubner MR, Metivier R, Brand H, Denger S, Manu D, Beaudouin J, Ellenberg J, Gannon F. 2003 Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol Cell 11:695\u2013707. https:\/\/doi.org\/S109727650300090X.","DOI":"10.1016\/S1097-2765(03)00090-X"},{"key":"2639_CR60","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s41568-022-00450-9","volume":"22","author":"L Wang","year":"2022","unstructured":"Wang L, Lankhorst L, Bernards R. Exploiting senescence for the treatment of cancer. Nat Rev Cancer. 2022;22:340\u201355. https:\/\/doi.org\/10.1038\/s41568-022-00450-9.","journal-title":"Nat Rev Cancer"},{"key":"2639_CR61","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1038\/s42255-019-0122-z","volume":"1","author":"A Guerrero","year":"2019","unstructured":"Guerrero A, Herranz N, Sun B, Wagner V, Gallage S, Guiho R, et al. Cardiac glycosides are broad-spectrum senolytics. Nat Metab. 2019;1:1074\u201388. https:\/\/doi.org\/10.1038\/s42255-019-0122-z.","journal-title":"Nat Metab"},{"key":"2639_CR62","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/iub.414","volume":"63","author":"P La Rosa","year":"2011","unstructured":"La Rosa P, Marino M, Acconcia F. 17 beta-estradiol regulates estrogen receptor alpha monoubiquitination. IUBMB Life. 2011;63:49\u201353. https:\/\/doi.org\/10.1002\/iub.414.","journal-title":"IUBMB Life"},{"key":"2639_CR63","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.steroids.2010.01.012","volume":"75","author":"IA Blair","year":"2010","unstructured":"Blair IA. Analysis of estrogens in serum and plasma from postmenopausal women: past present, and future. Steroids. 2010;75:297\u2013306. https:\/\/doi.org\/10.1016\/j.steroids.2010.01.012.","journal-title":"Steroids"},{"key":"2639_CR64","doi-asserted-by":"publisher","unstructured":"Bense RDdV EGE, Schroder CP, Fermann RSN. Higher expression of Estrogen response genes in the primary tumor is associated with a greater risk for late recurrence in patients with ER+\/HER2-breast cancer. Breast Cancer Early Stage. 2017;28. https:\/\/doi.org\/10.1093\/annonc\/mdx362.046.","DOI":"10.1093\/annonc\/mdx362.046"},{"key":"2639_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228807","author":"N Lee","year":"2020","unstructured":"Lee N, Park MJ, Song W, Jeon K, Jeong S. Currently applied molecular assays for identifying ESR1 mutations in patients with advanced breast cancer. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21228807.","journal-title":"Int J Mol Sci"},{"key":"2639_CR66","doi-asserted-by":"publisher","unstructured":"Lukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanislawek. A 2021 breast Cancer-Epidemiology, risk Factors, Classification, prognostic Markers, and current treatment Strategies-An updated review. Cancers (Basel) 13. https:\/\/doi.org\/10.3390\/cancers13174287.","DOI":"10.3390\/cancers13174287"},{"key":"2639_CR67","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1158\/2159-8290.CD-19-1390","volume":"10","author":"SA Wander","year":"2020","unstructured":"Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia JE, Lloyd MR, et al. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4\/6 inhibitors in patients with hormone receptor-positive metastatic breast cancer. Cancer Discov. 2020;10:1174\u201393. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-1390.","journal-title":"Cancer Discov"},{"key":"2639_CR68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002201","volume":"13","author":"C Lefebvre","year":"2016","unstructured":"Lefebvre C, Bachelot T, Filleron T, Pedrero M, Campone M, Soria JC, et al. Mutational profile of metastatic breast cancers: a retrospective analysis. PLoS Med. 2016;13:e1002201. https:\/\/doi.org\/10.1371\/journal.pmed.1002201.","journal-title":"PLoS Med"},{"key":"2639_CR69","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s43018-022-00491-x","volume":"4","author":"S Garcia-Recio","year":"2023","unstructured":"Garcia-Recio S, Hinoue T, Wheeler GL, Kelly BJ, Garrido-Castro AC, Pascual T, et al. Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. Nat Cancer. 2023;4:128\u201347. https:\/\/doi.org\/10.1038\/s43018-022-00491-x.","journal-title":"Nat Cancer"},{"key":"2639_CR70","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s43018-020-0050-6","volume":"1","author":"E Pleasance","year":"2020","unstructured":"Pleasance E, Titmuss E, Williamson L, Kwan H, Culibrk L, Zhao EY, et al. Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes. Nat Cancer. 2020;1:452\u201368. https:\/\/doi.org\/10.1038\/s43018-020-0050-6.","journal-title":"Nat Cancer"},{"key":"2639_CR71","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1158\/1078-0432.CCR-15-1534","volume":"22","author":"P Wang","year":"2016","unstructured":"Wang P, Bahreini A, Gyanchandani R, Lucas PC, Hartmaier RJ, Watters RJ, et al. Sensitive detection of mono- and polyclonal ESR1 mutations in primary tumors, metastatic lesions, and cell-free DNA of breast cancer patients. Clin Cancer Res. 2016;22:1130\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1534.","journal-title":"Clin Cancer Res"},{"key":"2639_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00709-4","volume":"10","author":"Z Li","year":"2024","unstructured":"Li Z, Chen F, Chen L, Liu J, Tseng D, Hadi F, et al. The EstroGene2.0 database for endocrine therapy response and resistance in breast cancer. NPJ Breast Cancer. 2024;10:106. https:\/\/doi.org\/10.1038\/s41523-024-00709-4.","journal-title":"NPJ Breast Cancer"},{"key":"2639_CR73","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.17548","author":"CT Stork","year":"2016","unstructured":"Stork CT, Bocek M, Crossley MP, Sollier J, Sanz LA, Chedin F, et al. Co-transcriptional R-loops are the main cause of estrogen-induced DNA damage. Elife. 2016. https:\/\/doi.org\/10.7554\/eLife.17548.","journal-title":"Elife"},{"key":"2639_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071583","author":"S Pescatori","year":"2021","unstructured":"Pescatori S, Berardinelli F, Albanesi J, Ascenzi P, Marino M, Antoccia A, et al. A Tale of Ice and Fire: The Dual Role for 17\u03b2-Estradiol in Balancing DNA Damage and Genome Integrity. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13071583.","journal-title":"Cancers (Basel)"},{"key":"2639_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143535","author":"Y Nagai","year":"2023","unstructured":"Nagai Y, Ambinder AJ. The Promise of Retinoids in the Treatment of Cancer: Neither Burnt Out Nor Fading Away. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15143535.","journal-title":"Cancers (Basel)"},{"key":"2639_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9020360","author":"L Costantini","year":"2020","unstructured":"Costantini L, Molinari R, Farinon B, Merendino N. Retinoic Acids in the Treatment of Most Lethal Solid Cancers. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9020360.","journal-title":"J Clin Med"},{"key":"2639_CR77","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.ctrv.2014.01.001","volume":"40","author":"E Garattini","year":"2014","unstructured":"Garattini E, Bolis M, Garattini SK, Fratelli M, Centritto F, Paroni G, et al. Retinoids and breast cancer: from basic studies to the clinic and back again. Cancer Treat Rev. 2014;40:739. https:\/\/doi.org\/10.1016\/j.ctrv.2014.01.001.","journal-title":"Cancer Treat Rev"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-025-02639-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02639-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02639-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T13:10:56Z","timestamp":1770124256000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-025-02639-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2639"],"URL":"https:\/\/doi.org\/10.1186\/s12964-025-02639-5","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"26 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"83"}}